Neuroscience Antibodies and Assays Market to grow by USD 1.83 billion from 2022 to 2027, North America to account for 46% of market growth- Technavio

NEW YORK, Sept. 10, 2023 /PRNewswire/ — The neuroscience antibodies and assays market size is expected to grow by USD 1.83 billion from 2022 to 2027. In addition, the momentum of the market will progress at a CAGR of 9.44% during the forecast period, according to Technavio Research. The market has been segmented by product (Consumables and Instruments), end-user (Pharmaceutical and biopharmaceutical companies, Academic and research institutes, and Hospital and diagnostic centers), and geography (North America, Europe, Asia, and Rest of World (ROW)). North America is estimated to contribute 46% of the global market during the forecast period. The rising need for diagnosing neurological disorders has led to an increased demand for neuroscience antibodies and assays. For instance, as of March 2021, an estimated 6.2 million Americans aged 65 years and older were living with Alzheimer’s Disease and dementia, and this figure is projected to reach 13.8 million by 2060. Consequently, the substantial prevalence of neurological disorders, the expanding aging population, significant healthcare expenditures allocated for neurological disease treatments, and favorable refund policies for neuro-diagnostic procedures are anticipated to be key drivers of market growth in the forecast period. This report offers an up-to-date analysis of the current market scenario, the latest trends and drivers, and the overall market environment. Read PDF Sample Report

Technavio has announced its latest market research report titled Global Neuroscience Antibodies and Assays Market

Company Profile:

Abcam plc, Abnova Corp., ADx NeuroSciences NV, Bio Rad Laboratories Inc., Biosensis Pty Ltd., BMG LABTECH GmbH, Cell Signaling Technology Inc., Chemie Brunschwig AG, Elabscience Biotechnology Inc., Enzo Biochem Inc., F. Hoffmann La Roche Ltd., GenScript Biotech Corp., Merck and Co. Inc., NSJ Bioreagents, PerkinElmer Inc., Proteintech Group Inc., Rockland Immunochemicals Inc., Santa Cruz Biotechnology Inc., Siemens AG, and Thermo Fisher Scientific Inc.

Abcam plc – The company offers neuroscience antibodies and assays that include anti-Ki67 antibodies, anti-vimentin antibodies, anti-beta catenin antibodies and anti-BrdU antibodies.

  To gain access to more vendor profiles available with Technavio, buy the report!

Neuroscience Antibodies And Assays Market: Segmentation Analysis

The market has been segmented by product (Consumables and Instruments), end-user (Pharmaceutical and biopharmaceutical companies, Academic and research institutes, and Hospital and diagnostic centers), and geography (North America, Europe, Asia, and Rest of World (ROW)). 

  • The market share growth by the consumables segment will be significant during the forecast period. In neuroscience assays, a diverse array of antibodies, assay kits, and reagents find application in the exploration of novel disease targets, enabling high-throughput screening of clinical compounds, gaining insights into the mechanism of action, and the creation of clinically relevant biomarkers.

Learn about the contribution of each segment summarized in concise infographics and thorough descriptions. View a PDF Sample Report

“Besides analyzing the current market scenario, our report examines historic data from 2017 to 2021”- Technavio

Neuroscience Antibodies And Assays Market: Driver & Trend:

Recombinant-based engineering is a significant advance in antibody manufacturing techniques, providing chemically defined and highly pure antibodies with several advantages over traditional antibodies is notably driving the market growth. Recombinant antibodies offer a unique advantage as they are monovalent and can be precisely engineered at the genetic level, opening up a range of possibilities not attainable through conventional antibody technologies. Moreover, their production doesn’t require hybridomas or involve animals, making them a more ethically sound choice. Consequently, there’s a rising demand for recombinant antibodies in neuroscience research. Recent advancements in immunoassay analyzers, including no-wash ELISAs, streamlined assay protocols, and automated systems, have significantly enhanced the efficiency of immunoassay workflows, reducing both time and labour while minimizing human errors. Furthermore, the advent of next-generation microplate readers featuring EDR technology has accelerated assay speed, increased sensitivity, and simplified measurement setup, collectively propelling growth in the global neuroscience antibodies and assays market during the forecast period.  Identify key trends, drivers, and challenges in the market. Download sample to gain access to this information.

What are the key data covered in this neuroscience antibodies and assays market report?

  • CAGR of the market during the forecast period
  • Detailed information on factors that will drive the growth of the neuroscience antibodies and assays market between 2022 and 2027.
  • Precise estimation of the neuroscience antibodies and assays market size and its contribution to the market in focus on the parent market
  • Accurate predictions about upcoming trends and changes in consumer behaviour
  • Growth of the market across North America, Europe, Asia, and ROW
  • A thorough analysis of the market’s competitive landscape and detailed information about vendors
  • Comprehensive analysis of factors that will challenge the growth of neuroscience antibodies and assays market vendors.

Related Reports:

The bispecific antibodies for cancer market is estimated to grow at a CAGR of 8.82% between 2022 and 2027. The size of the market is forecast to increase by USD 400.72 million.  This report extensively covers market segmentation by type (CD19 or SC3 and CD30 or CD16A), distribution channel (hospitals, retail pharmacies, and online), and geography (North America, Europe, Asia, and Rest of World (ROW)).  The increasing prevalence of cancer is notably driving market growth.

The antinuclear antibody test market share is expected to increase to USD 447.71 million from 2021 to 2026, and the market’s growth momentum will accelerate at a CAGR of 7.93%. This report extensively covers antinuclear antibody test market segmentation by end-user (hospitals and clinical diagnostic laboratories) and geography (North America, Europe, Asia, and Rest of World (ROW)). One of the key factors driving the global antinuclear antibody test market growth is the increasing demand for ANA tests. 


Executive Summary

Market Landscape

Market Sizing

Historic Market Sizes

Five Forces Analysis

Market Segmentation by Product

Market Segmentation by End-user

Customer Landscape

Geographic Landscape

Drivers, Challenges, & Trends

Company Landscape

Company Analysis


About Technavio

Technavio is a leading global technology research and advisory company. Their research and analysis focuses on emerging market trends and provides actionable insights to help businesses identify market opportunities and develop effective strategies to optimize their market positions. With over 500 specialized analysts, Technavio’s report library consists of more than 17,000 reports and counting, covering 800 technologies, spanning across 50 countries. Their client base consists of enterprises of all sizes, including more than 100 Fortune 500 companies. This growing client base relies on Technavio’s comprehensive coverage, extensive research, and actionable market insights to identify opportunities in existing and potential markets and assess their competitive positions within changing market scenarios.


Technavio Research

Jesse Maida

Media & Marketing Executive

US: +1 844 364 1100

UK: +44 203 893 3200

Email: [email protected]


Cision View original content to download multimedia:–north-america-to-account-for-46-of-market-growth–technavio-301921848.html

SOURCE Technavio


Source link

The content is by PR Newswire. Headlines of Today Media is not responsible for the content provided or any links related to this content. Headlines of Today Media is not responsible for the correctness, topicality or the quality of the content.

Back to top button